Dr. Sergey Zhuplatov, MD, PhD - Sanofi Aventis  - Global Clinical Research Director

Dr. Sergey Zhuplatov

MD, PhD

Sanofi Aventis

Global Clinical Research Director

Southampton, PA | United States

Main Specialties: Cardiovascular Disease, Endocrinology Diabetes & Metabolism, Internal Medicine

Additional Specialties: Internal Medicine, Endocrinology, Cardiology

ORCID logohttps://orcid.org/0000-0001-9632-4744


Top Author

Dr. Sergey Zhuplatov, MD, PhD - Sanofi Aventis  - Global Clinical Research Director

Dr. Sergey Zhuplatov

MD, PhD

Introduction

Dr. Sergey Zhuplatov is a Global Clinical Research Director of Cardio-Metabolic R&D Department of Sanofi, previously worked as a Global Director of Clinical Affairs Ascensia Diabetes Care, and a Medical Director of the Metabolic Strategy and Development of AstraZeneca LP. Fort Washington, PA. He was graduated as MD at the Izhevsk State Medical Academy in Russia before finishing his fellowship in Internal Medicine/Endocrinology at Moscow Academy of Post diploma Education and Moscow Medical Institute of Transplantology in 1986. He accepted tenure and leading clinical consultant position in Endocrinology/Cardiology clinic at his Alma Mater ISMA. At this time, he started his Ph.D. dissertation in Cardiology with prevention of progressive CV events in Diabetes Mellitus Patients as the main topic, which was perfectly defended at Ural State Medical Academy on 1991. Dr. Zhuplatov has been working as an Assistant Professor and practicing physician till his emigration to the USA in 2002 as an exceptional ability person visa waiver. Before that he worked 2 years as a Medical Scientific Consultant for Merck S&D Co., and also as a Chief Medical Officer in Private Medical Clinic for 2 years. He published different works in Internal Medicine, Lipidology, Endocrinology, and Cardiology. He continued his scientific work in University of Utah Medical School till his merge to Pharmaceutical Industry in 2008. Since then he is working in Cardio/Metabolic area of Medical Affairs and Clinical Development of Bristol-Meyers Squibb and AstraZeneca Co.

Primary Affiliation: Sanofi Aventis - Southampton, PA , United States

Specialties:

Additional Specialties:

Research Interests:


View Dr. Sergey Zhuplatov’s Resume / CV

Education

Sep 1986 - Oct 1991
Ural State Medical University
PhD
Cardiology
Sep 1986
Izhevsk Stte Medical Academy
Fellowship
Endocrinology
Jul 1984
Izhevsk State Medical Academy
MD
Internal Medicine

Experience

Jul 2018 - Jun 2018
Sanofi-Aventis US LLC
Global Clinical Research Director
Cardio-Metabolic
Dec 2016 - Dec 2016
Ascensia Diabetes Care Inc.
Director
Global Clinical Affairs
Feb 2016
24 hr. CGM level in Dapagliflozin treatment
Medical Monitor
Published in 2016
Dec 2015
24 hr. CGM level in Exenatide treatment
Medical Monitor
Published in 2016
Jun 2012 - Jun 2013
Bristol Myers Squibb Co
Associate Medical Director
Strategy and Development Diabetes
Jun 2013 - Jan 2013
AstraZeneca
Director of Medical Alignment
Strategy and Development Diabetes
Jun 2008 - Jun 2012
Bristol Myers Squibb Co
MSL
Medical Affairs
Dec 2005 - May 2008
University of Utah Hospital
Sr. Scientist
Radiation Oncology
May 2000 - May 2002
University of Utah
Post Doc
Nephrology
May 2000 - May 2000
EXCI LLC
CEO
Executive
Jun 1989 - May 1991
Izhevsk State Medical Academy
Assistant Clinical Professor
Internal Medicine

Publications

25Publications

212Reads

376Profile Views

21PubMed Central Citations

Removal of Endotoxins and Cytokines by Plasmapheresis Filtration with Plasma Exchange Therapy (TPE) Could Benefit Patients with Covid-19 in Critical Condition.

J Anest & Inten Care Med 10(5): JAICM.MS.ID.555798 (2020). DOI:10.19080/JAICM.2020.10.555798.

J Anest & Inten Care Med.

AbstractBackground: The COVID-19 pandemic originated in Wuhan, China is rapidly and continuously spreading globally and can result in significant severe respiratory morbidity and mortality. The severe damage of the lung tissue can result in acute respiratory distress syndrome (ARDS), which can further precipitate septic shock. These two complications are the major contributors to the intensive care unit (ICU) care and mortality from COVID-19 in patients older than 60 years, with smoking history, and comorbid medical conditions. The possible high mortality rate of COVID-19 can be connected to the increasing of Th17 cells activity mainly stimulated by IL-6 and IL-23. Discussion: The mitigation of morbidity risk in patients with COVID-19 infection in the progression of acute respiratory distress syndrome (ARDS) related to severe respiratory tract damage with the high blood level of inflammatory markers as Cytokines IL-6 is an essential goal of contemporary treatment these patients in ICU environment. The Plasma Exchange therapy (TPE) with continuous hemofiltration (CHF) reduced level IL-6 and other cytokines in patients with different critical pathologies as fulminant liver damage, autoimmune inflammation, neurological and infectious diseases. Conclusion: CHF with TPE treatment can be one of the ways of concomitant therapy in the standard of care for COVID-19 infection patients with developing respiratory distress syndrome. However, further investigations are necessary in order to corroborate this successful therapy.Keywords: COVID-19; Cytokines storm; IL-6; ARDS; Plasmapheresis; TPE; Plasma exchange therapy; Hemofiltration Abbreviations: ASFA: The American Society for Apheresis; COVID-19: Coronavirus Disease 2019; ICU: Intensive Care Unit; ARDS: Respiratory Distress Syndrome; CRS: The Systemic Inflammatory Response; TPE: Therapeutic Plasma Exchange; CHF: Continuous Hemofiltration; CHDF: Continuous Hemodiafiltration; PF: Plasmafiltration; IL-16: Interleukin-16; IL-23: Interleukin-23; Th17 , Th-0: T- Helper Lymphocytes-17(0)

View Article
May 2020
70 Reads

Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial.

Diabetes Technol Ther 2018 11 14;20(11):715-724. Epub 2018 Sep 14.

5 AstraZeneca , Fort Washington, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/dia.2018.0052DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208164PMC
November 2018
84 Reads
2.110 Impact Factor

Exenatide once weekly improved 24-hour glucose control and reduced glycaemic variability in metformin-treated participants with type 2 diabetes: a randomized, placebo-controlled trial.

Diabetes Obes Metab 2017 Jan 21;19(1):40-48. Epub 2016 Sep 21.

Integrated Medical Development, Princeton Junction, New Jersey, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dom.12763DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168745PMC
January 2017
8 Reads
2 Citations
6.360 Impact Factor

Effect of Exenatide Once Weekly on Glycemic Fluctuations in Patients with T2D,

ADA 76th Congress, 2016, June 10-14th, New Orleans, LA, 1014-P

Glycemic fluctuations are an important clinical consideration when managing patients with T2D. This randomized controlled double-blind phase 4 clinical study (NCT02288273) investigated the quality of glucose control with exenatide QW (EQW) versus placebo (PBO) using continuous glucose monitoring (CGM). Patients with T2D inadequately controlled on metformin (MET) were randomized to EQW 2 mg or PBO for 10 wks. Glucose concentration was measured over 7 days at baseline and Wks 4 and 10 using CGM (Dexcom G4). At baseline mean age, A1C, fasting plasma glucose (FPG) and 2h postprandial glucose (PPG) in the EQW (N=60)/PBO (N=56) groups were 55/56 y, 8.2%/8.0%, 178/168 mg/dL and 221/221 mg/dL, respectively. Compared with PBO (LS mean treatment difference for change from baseline), EQW significantly (P<0.001) reduced 24h mean weighted glucose (Wks 4, 10: −21 mg/dL; −28 mg/dL), FPG (−28 mg/dL; −37 mg/dL), and PPG (−30 mg/dL; −38 mg/dL). There was no difference in mean weighted glucose on Day 1 and Day 6 of Wk 10 with EQW (150; 151 mg/dL). EQW resulted in a significantly (P<0.001) greater reduction in mean amplitude of glucose excursions (MAGE) versus PBO at Wk 10 (−18 mg/dL). Time in the euglycemic range significantly (P<0.001) increased from baseline to Wks 4 and 10 in the EQW group, through reductions in the hyperglycemic range with no increase in time in the hypoglycemic range. For EQW vs PBO, time in euglycemic range was 53% vs 55% at baseline, 71% vs 60% at Wk 4, and 77% vs 58% at Wk 10. Time in hyperglycemic range was 47% vs 45%, 29% vs 40%, and 22% vs 42%. Time in hypoglycemic range was 0.1% vs 0.1%, 0.6% vs 0.3%, and 0.7% vs 0.3%. In patients with T2D uncontrolled on MET, EQW significantly improved overall glycemic control and reduced glucose fluctuations as early as Wk 4, as determined by reductions in FPG, PPG, 24h mean weighted glucose, MAGE, and time in the hyperglycemic range. Improvements in glycemic control were not accompanied by an increase in hypoglycemia and glycemic control was consistent throughout Wk 10 as shown by 24h glucose.

View Article
June 2016
14 Reads

Effects of Exenatide Once Weekly on Dynamics of 24h Glucose Patterns in Patients with T2D

ADA 76th Congress, 2016, June 10-14th, New Orleans, LA1048-P

ADA 76th Congress, 2016, June 10-14th, New Orleans

Reducing glycemic fluctuations is an important component of glucose control. This randomized, controlled, double-blind, phase 4 clinical study (NCT02288273) investigated glucose fluctuations with the GLP-1 receptor agonist exenatide QW (EQW) versus placebo (PBO) using continuous glucose monitoring (CGM). Patients with T2D uncontrolled on background metformin (MET) were randomized to EQW 2 mg or PBO for 10 wks. Glucose concentration was measured over 7d at lead-in and Wks 4 and 10 using CGM (Dexcom G4). In the EQW (N=60)/PBO (N=56) groups, mean baseline age was 55/56 y and A1C was 8.2/8.0%. A measure of glucose fluctuation, distance traveled (arc length of the mean 24h glucose curve), decreased with EQW compared to PBO (Wk 10: −81 mg/dL over 24h, P=0.004) from a baseline of 755/730 mg/dL over 24h, and another, total energy (sum of squared frequency times amplitude of Fourier coefficients for the 24h individual average glucose curves averaged for a week over 24h) also decreased with EQW compared to PBO [Wk 10: −4893 (mg/(dL*h))2 over 24h, P=0.003] from a baseline of 12341/9953 (mg/(dL*h))2 over 24h. Energy spectrum analysis showed the reduction was confined to slower glucose changes rather than fast changes (Fig) and indicated substantial differences depending on mean glucose and age (not shown). Thus EQW significantly reduced measures of glucose fluctuation, such as distance traveled and energy, compared with PBO.

View Article
June 2016
23 Reads

Effect of exenatide once weekly on quality of glycemic control in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

Endocr Rev 2016;37:From the Endocrine Society's 98th Annual Meeting and Expo, April 91–94, 2016, Bos

Endocr Rev

Excessive glycemic fluctuations, characterized by exaggerated postprandial glucose (PPG) excursions and hypoglycemia, may provide important data to consider, in addition to A1C, when treating patients with diabetes. Exenatide once weekly (QW) has been shown to significantly improve glycemic control in patients with type 2 diabetes (T2D) in a glucosedependent manner, with body weight reduction and no increased risk of hypoglycemia. The objective of this randomized, controlled, double-blind, phase 4 clinical study (NCT02288273) was to investigate the quality of glucose control with exenatide QW compared with placebo (PBO) based on the 24-h glucose profile obtained from continuous glucose monitoring (CGM). Patients with T2D inadequately controlled on a background of metformin (MET) therapy were randomized 1:1 to exenatide QW 2 mg or PBO for 10 weeks. Glucose concentration was measured over 7 days at lead-in and Weeks 4 and 10 using a CGM system (Dexcom G4); 2-h PPG and fasting plasma glucose (FPG) were laboratory measures. The primary outcome was change from baseline in 24-h mean weighted glucose at Weeks 4 and 10 in the modified intent-to-treat population. In the exenatide QW (n=60) and PBO (n=56) groups, mean baseline age was 55 and 56 y, A1C was 8.2% and 8.0%, and FPG was 178 and 168 mg/dL, respectively. Compared with PBO, exenatide QW significantly (P<0.001) reduced mean weighted glucose from baseline to Week 4 (−26.0 ± 3.6 mg/dL vs −5.3 ± 3.9 mg/dL; difference: −20.8 ± 5.3 mg/dL) and Week 10 (−30.8 ± 4.5 mg/dL vs −3.0 ± 4.8 mg/dL; difference: −27.8 ± 6.6 mg/dL). 2-h PPG reductions were significantly (P<0.001) greater with exenatide QW versus PBO at Week 4 (−32 mg/dL vs −2 mg/dL; difference: −30 mg/dL), and Week 10 (−44 mg/dL vs −6 mg/dL; difference: −38 mg/dL). FPG reductions were significantly (P<0.001) greater with exenatide QW versus PBO at Week 4 (−30 mg/dL vs −2 mg/dL; difference: −28 mg/dL) and Week 10 (−42 mg/dL vs −5 mg/dL; difference: −37 mg/dL). Exenatide QW was not associated with an increased risk of hypoglycemia; the change in the proportion of time with blood glucose <70 mg/dL from baseline (measured by CGM) was similar with exenatide QW and PBO (0.5% vs 0.1%; P=0.115). The most common adverse events (AEs) were mild injection-site nodule (exenatide QW, 10.0%; placebo, 0.0%), mild-to-moderate urinary tract infection (6.7% and 8.9%), and mild-to-moderate nausea (6.7% and 0.0%). In patients with T2D uncontrolled on MET, exenatide QW was well tolerated and improved glycemic fluctuations compared with PBO, as shown by reductions in 24-h mean weighted glucose, PPG, and FPG, without increasing the risk of hypoglycemia or unexpected AEs. Significant, clinically relevant reductions in PPG and FPG with exenatide QW occurred at first assessment at Week 4, with further reductions at Week 10.

View Article
March 2016
18 Reads

An Obesity Therapeutic Treatment as a Modern Pharmaceutical Industry Challenge

Zhuplatov SB (2015) An Obesity Therapeutic Treatment as a Modern Pharmaceutical Industry Challenge.

Pharm Pharmacol Int J

An obesity therapeutic treatment as a modern pharmaceutical industry challenge

View Article
July 2015
17 Reads

Dipyridamole (DIP)-induced increases in cAMP and cGMP correlate with inhibition of vascular smooth muscle cell (SMC) proliferation

Authors:
Zhuplatov SB

Journal of the American Society of Nephrology : JASN; v:14 p:505A; 11/2003 American Society of Nephr

Journal of the American Society of Nephrology : JASN

View Article
November 2011
21 Reads

The nuclear matrix shell proteome of human epidermis.

J Dermatol Sci 2010 May 6;58(2):113-22. Epub 2010 Mar 6.

Department of Radiation Oncology, University of Utah Health Sciences Center, Salt Lake City, UT 84132, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdermsci.2010.03.001DOI Listing
May 2010
72 Reads
2 Citations
3.420 Impact Factor

Protein phosphorylation in irradiated human melanoma cells.

Radiat Res 2007 Nov;168(5):535-44

Department of Radiation Oncology, University of Utah Health Sciences Center, Salt Lake City, UT 84132, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1667/RR0404.1DOI Listing
November 2007
7 Reads
2.911 Impact Factor

Mechanism of dipyridamole's action in inhibition of venous and arterial smooth muscle cell proliferation.

Basic Clin Pharmacol Toxicol 2006 Dec;99(6):431-9

Veterans Affairs Salt Lake City Healthcare System, Departments of Medicine, Pharmacology & Toxicology, and Biochemistry, University of Utah, Salt Lake City, Utah, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1742-7843.2006.pto_516.xDOI Listing
December 2006
6 Reads
5 Citations
2.380 Impact Factor

Inhibition of neointimal hyperplasia in vascular grafts by sustained perivascular delivery of paclitaxel.

Kidney Int 2004 Nov;66(5):2061-9

Departments of Medicine, Bioengineering, Pathology, Pharmaceutics, and Surgery, and Animal Resource Center, University of Utah, Salt Lake City, Utah, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1523-1755.2004.00985.xDOI Listing
November 2004
11 Reads
12 Citations
8.563 Impact Factor

[The functional dynamics of capillary blood flow in patients with IHD combined with diabetes mellitus].

Authors:
S B Zhuplatov

Ter Arkh 1994 ;66(12):11-3

View Article

Download full-text PDF

Source
April 1995
10 Reads
0.190 Impact Factor

The peculiarity of Cardio-hemodynamic in Diabetes Mellitus

Problemy Endocrinologii (Endocrinology Problems) 1995,2:p.6-10.(Russian)

Problemy Endocrinologii (Endocrinology Problems) (Russia)

Conjunctival microscopy of capillaries evidences specific changes in microcirculation in Diabetes Mellitus Patients. Criteria of different condition were elaborated as a diagnostic tool.

View Article
17 Reads

The combination therapy of hyperlipidemia in metabolic syndrome with coronary artery disease

Diabetes Research and Clinical Practice 50 (0) (2000) pp. 321-321

Diabetes Research and Clinical Practice

Afferent therapy of lipids improved the cardiovascular parameters in T2 Diabetes Mellitus Patients with progressive Coronary Heart Disease.

View Article
12 Reads

Dipyridamole (DIP)-induced Increases in cAMP and cGMP Correlate with Inhibition of Vascular Smooth Muscle Cell (SMC).

J.Am.Soc. Nephrology, 14:2003, ASN Program & Abstracts 36th Annual Meeting 2003, 505A, SA-PO936.

J.Am.Soc. Nephrology

View Article
63 Reads